Vascular disease as a predictor of long-term mortality in patients hospitalized for new-onset heart failure

Archives of Cardiovascular Diseases

Volumn 102, Issue 1, 2009, Pages 11-18

  Tartière, Jean Michel ^a   Kesri Tartière, Lamia ^b   Rusinaru, Dan ^c   Lévy, Franck ^c   Tribouilloy, Christophe ^c  

^a General Hospital   (France)

^b BICHAT HOSPITAL   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Heart failure; Prognosis; Vascular disease

Indexed keywords

ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; AGED; ARTERY DISEASE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HEART DEATH; HEART FAILURE; HOSPITAL PATIENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL VASCULAR DISEASE; PROGNOSIS; PROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; STROKE; SURVIVAL TIME;

EID: 63049106328     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2008.10.011     Document Type: Article

References (41)

1. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998;98:2282-9.
2. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
3. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999;33:1948-55.
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
5. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353:2001-7.
6. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.
7. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
8. Goldberg RJ, Ciampa J, Lessard D, Meyer TE, Spencer FA. Long-term survival after heart failure: a contemporary population-based perspective. Arch Intern Med 2007;167:490-6.
9. Heywood JT, Etatre W, Pai RG, Fabbri S, Huiskes B. Simple clinical criteria to determine the prognosis of heart failure. J Cardiovasc Pharmacol Ther 2005;10:173-80.
10. Jones RC, Francis GS, Lauer MS. Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group trial. J Am Coll Cardiol 2004;44:1025-9.
11. Kamalesh M, Subramanian U, Sawada S, Eckert G, Temkit M, Tierney W. Decreased survival in diabetic patients with heart failure due to systolic dysfunction. Eur J Heart Fail 2006;8:404-8.
12. Beguin M, Houpe D, Peltier M, Chapelain K, Lesbre JP, Tribouilloy C. Epidemiology and aetiology of cardiac failure in the Somme. Arch Mal Coeur Vaiss 2004;97:113-9.
13. Houpe D, Peltier M, Cohen-Sotal A, et al. Heart failure due to left ventricular systolic dysfunction: treatment at discharge from hospital and at 1 year. Int J Cardiol 2005;103:286-92.
14. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441-6.
15. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J 1999;20:421-8.
16. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54.
17. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47.
18. Mozaffarian D, Anker SD, Anand I, et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 2007;116:392-8.
19. Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JG, Massie BM, Ryden L. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003;89:42-8.
20. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/ Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463-654.
21. Arima H, Tzourio C, Butcher K, et al. Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial. Stroke 2006;37:1497-502.
22. Campbell DJ, Woodward M, Chalmers JP, et al. Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension 2005;45:69-74.
23. Eagle KA, Rihal CS, Foster ED, Mickel MC, Gersh BJ. Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigators. J Am Coll Cardiol 1994;23:1091-5.
24. Guerrero M, Harjai K, Stone GW, et al. Usefulness of the presence of peripheral vascular disease in predicting mortality in acute myocardial infarction patients treated with primary angioplasty (from the Primary Angioplasty in Myocardial Infarction Database). Am J Cardiol 2005;96:649-54.
25. Huynh BC, Rovner A, Rich MW. Long-term survival in elderly patients hospitalized for heart failure: 14-year follow-up from a prospective randomized trial. Arch Intern Med 2006;166:1892-8.
26. Lamina C, Meisinger C, Heid IM, et al. Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. Eur Heart J 2006;27:2580-7.
27. Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004;109:733-9.
28. Sikkink CJ, van Asten WN, van't Hof MA, van Langen H, van der Vliet JA. Decreased ankle/brachial indices in relation to morbidity and mortality in patients with peripheral arterial disease. Vasc Med 1997;2:169-73.
29. Kelly R, Staines A, MacWalter R, Stonebridge P, Tunstall-Pedoe H, Struthers AD. The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes: a case-controt study. J Am Coll Cardiol 2002;39:219-24.
30. Svensson P, de Faire U, Niklasson U, Hansson LO, Ostergren J. Plasma NT-proBNP concentration is related to ambulatory pulse pressure in peripheral arterial disease. Blood Press 2005;14:99-106.
31. Aukrust P, Gullestad L, Ueland T, Damas JK, Yndestad A. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med 2005;37:74-85.
32. Heinecke JW. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol 2003;91:12A-6A.
33. Levy BI. How to explain the differences between renin angiotensin system modulators. Am J Hypertens 2005;18:134S-41S.
34. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet 2006;367: 356-67.
35. Domanski MJ, Mitchell GF, Norman JE, Exner DV, Pitt B, Pfeffer MA. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol 1999;33:951-8.
36. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004;43:635-41.
37. Piepoli MF, Davos C, Francis DP, Coats AJ. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004;328:189.
38. Adams Jr HP, det Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool. for neurologists. Stroke 2007;38: 1655-711.
39. Tartiere JM, Kesri L, Safar H, et al. Association between pulse pressure, carotid intima-media thickness and carotid and/or iliofemoral plaque in hypertensive patients. J Hum Hypertens 2004;18:325-31.
40. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004;43:1439-44.
41. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001;358:351-5.